

Miguel Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2029886/publications.pdf>

Version: 2024-02-01

437
papers

29,299
citations

5569

82
h-index

5986

160
g-index

447
all docs

447
docs citations

447
times ranked

25140
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1383-1390.	3.2	12
2	HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. <i>Cancers</i> , 2022, 14, 512.	1.7	2
3	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
4	How we treat HR-positive, HER2-negative early breast cancer. <i>Future Oncology</i> , 2022, 18, 1003-1022.	1.1	11
5	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
6	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1854-1862.	3.2	5
7	Prognosis and correlation with Ca19.9 of circulating tumor cells (CTCs) in locally advanced and metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 586-586.	0.8	0
8	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 625-634.	1.9	4
9	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , 2022, 82, GS1-07-GS1-07.	0.4	0
10	Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 1343-1346.	1.3	3
11	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
12	Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS). <i>Cancer Research</i> , 2022, 82, PD13-01-PD13-01.	0.4	1
13	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	5.1	4
14	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24.	1.3	9
15	The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0. <i>Supportive Care in Cancer</i> , 2022, 30, 6745-6754.	1.0	2
16	Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 1190.	3.4	21
17	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	0.8	4
18	Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1108-TPS1108.	0.8	2

#	ARTICLE	IF	CITATIONS
19	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	1.1	23
20	Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. <i>Clinical and Translational Oncology</i> , 2021, 23, 122-129.	1.2	2
21	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 462-470.	2.3	6
22	Aggressiveness of end-of-life cancer care: what happens in clinical practice?. <i>Supportive Care in Cancer</i> , 2021, 29, 3121-3127.	1.0	6
23	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
24	At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. <i>Journal of Leukocyte Biology</i> , 2021, 109, 953-967.	1.5	15
25	Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer. <i>Mathematics</i> , 2021, 9, 222.	1.1	2
26	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice. <i>Supportive Care in Cancer</i> , 2021, 29, 4673-4681.	1.0	0
27	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	2.3	331
28	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38
29	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
30	Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 814-818.	0.6	4
31	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. <i>Scientific Reports</i> , 2021, 11, 7064.	1.6	13
32	Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. <i>Annals of Oncology</i> , 2021, 32, 488-499.	0.6	69
33	How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer. <i>Oncology and Therapy</i> , 2021, 9, 297-309.	1.0	2
34	aceLERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1100-TPS1100.	0.8	4
35	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , 2021, 39, 1507-1508.	0.8	0
36	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153

#	ARTICLE	IF	CITATIONS
37	Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2021, 39, 517-517.	0.8	3
38	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. Npj Breast Cancer, 2021, 7, 80.	2.3	31
39	Alpelisib in combination with everolimus±Aexemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer, 2021, 151, 49-62.	1.3	19
40	DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. Journal of Personalized Medicine, 2021, 11, 792.	1.1	2
41	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of Oncology, 2021, 32, 1015-1024.	0.6	144
42	Venous thromboembolism incidence in cancer patients with germline BRCA mutations. Clinical and Translational Oncology, 2021, , 1.	1.2	1
43	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Research and Treatment, 2021, 189, 689-699.	1.1	21
44	Technical Challenges for CTC Implementation in Breast Cancer. Cancers, 2021, 13, 4619.	1.7	13
45	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 2021, 13, 4421.	1.7	12
46	Trajectories of alcohol consumption during life and the risk of developing breast cancer. British Journal of Cancer, 2021, 125, 1168-1176.	2.9	17
47	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of Oncology, 2021, 32, 1571-1581.	0.6	225
48	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	13.9	363
49	Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. Clinical and Translational Oncology, 2020, 22, 717-724.	1.2	7
50	Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. Clinical and Translational Oncology, 2020, 22, 555-562.	1.2	14
51	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer, 2020, 20, e173-e180.	1.1	21
52	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. Clinical and Translational Oncology, 2020, 22, 1049-1058.	1.2	0
53	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2~ Breast Cancer. Clinical Cancer Research, 2020, 26, 566-580.	3.2	125
54	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Na~ve Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 110-121.	3.2	120

#	ARTICLE	IF	CITATIONS
55	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). <i>Journal of Clinical Oncology</i> , 2020, 38, 203-213.	0.8	87
56	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10
57	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	13.9	482
58	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72.	5.1	161
59	Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid. <i>Frontiers in Oncology</i> , 2020, 10, 1777.	1.3	28
60	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , 2020, 54, 148-154.	0.9	25
61	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain. <i>Oncologist</i> , 2020, 25, e1339-e1345.	1.9	14
62	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020, 10, 7741.	1.6	9
63	Association Between <i>ABCB1</i> Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer. <i>JAMA Dermatology</i> , 2020, 156, 987.	2.0	8
64	Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 2763-2778.	1.1	8
65	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , 2020, 12, 3132.	1.7	11
66	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 ⁺ , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
67	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
68	Reply to Y. Usui et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2113-2114.	0.8	0
69	Nephrotic syndrome in a 60-year-old man. <i>Journal of Clinical Pathology</i> , 2020, 73, e3-e3.	1.0	0
70	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. <i>Future Oncology</i> , 2020, 16, 1165-1177.	1.1	2
71	Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR +, HER2 ⁺ Advanced Breast Cancer. <i>Oncologist</i> , 2020, 25, e1346-e1354.	1.9	28
72	Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. <i>Clinical and Translational Oncology</i> , 2020, 22, 1857-1866.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz085.	1.4	24
74	Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases. Oncologist, 2020, 25, e861-e869.	1.9	3
75	Exercise and cancer: a position statement from the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 1710-1729.	1.2	43
76	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 364-372.	3.2	29
77	Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study. , 2020, , .		3
78	Abstract CT071: Talazoparib (TALA) in germlineBRCA1/2(gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial. , 2020, , .		4
79	Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Research, 2020, 80, GS1-07-GS1-07.	0.4	13
80	Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). , 2020, , .		13
81	Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. Cancer Research, 2020, 80, GS5-01-GS5-01.	0.4	19
82	Abstract OT1-08-06: International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS). , 2020, , .		2
83	Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer. , 2020, , .		7
84	Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC). , 2020, , .		0
85	Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study. , 2020, , .		0
86	Abstract OT2-02-02: MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. , 2020, , .		0
87	Abstract CT072: Exploration of impact of tumorBRCAzygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2 ⁻) advanced breast cancer (ABC) and a germlineBRCA1/2(gBRCA1/2) mutation. , 2020, , .		2
88	Abstract P1-10-09: The MHCII immune activation assay is prognostic for disease free survival in basal-like TNBC breast cancer patients in the GEICAM/9906 clinical trial. , 2020, , .		0
89	Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3). , 2020, , .		0
90	Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2). Cancer Research, 2020, 80, OT2-07-01-OT2-07-01.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Abstract P1-19-21: Ribociclib + letrozole in patients with HR+, HER2 ⁺ advanced breast cancer: Safety analysis of the phase 3b ComPLEment-1 trial. , 2020, , .		0
92	Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers. , 2020, , .		0
93	387â€¦A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. , 2020, , .		4
94	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothed or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012â€“12 (EDALINE) study. Investigational New Drugs, 2019, 37, 98-108.	1.2	33
95	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2â€“positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125, 3974-3984.	2.0	67
96	Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptorâ€“positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. European Journal of Cancer, 2019, 117, 91-98.	1.3	17
97	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell, 2019, 179, 1191-1206.e21.	13.5	291
98	Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. Breast Cancer Research and Treatment, 2019, 175, 129-139.	1.1	14
99	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer, 2019, 5, 5.	2.3	352
100	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Annals of Oncology, 2019, 30, 567-574.	0.6	19
101	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer, 2019, 19, 517.	1.1	42
102	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology, 2019, 37, 2206-2216.	0.8	152
103	Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. BMC Genomics, 2019, 20, 452.	1.2	36
104	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2 ⁻) early breast cancer (EBC): results from the GEICAM/2006â€“10 study. Breast Cancer Research and Treatment, 2019, 177, 115-125.	1.1	20
105	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961.	1.1	58
106	Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial. Breast, 2019, 44, S18-S19.	0.9	0
107	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	1.3	8
108	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment, 2019, 176, 377-386.	1.1	61

#	ARTICLE	IF	CITATIONS
109	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
110	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019, 9, 3904.	1.6	23
111	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€™298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
112	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	1.9	43
113	RIBOCICLIB (RIB) + LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL RECEPTOR-2â€™NEGATIVE (HER2â€™) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL. <i>Breast</i> , 2019, 48, S46.	0.9	0
114	A PLAIN-LANGUAGE SUMMARY OF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER. <i>Breast</i> , 2019, 48, S49-S50.	0.9	0
115	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Tj ETQq1 1 0.784314 rgBT /Over	1.6	11
116	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	7
117	Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. <i>JAMA Oncology</i> , 2019, 5, 366.	3.4	26
118	Interim results from the full population of the phase 3b CompleEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2â€™ advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1041-1041.	0.8	7
119	Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1071-1071.	0.8	1
120	Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2606-2606.	0.8	2
121	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 500-500.	0.8	5
122	Incidence of venous thromboembolic disease (VTE) in a cohort of patients with colorectal cancer (CRC) according to KRAS, NRAS and BRAF status.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15136-e15136.	0.8	2
123	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptorâ€™positive (HR+), human epidermal growth factor receptor 2â€™negative (HER2â€™) early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS597-TPS597.	0.8	44
124	Retrospective analysis of clinical characteristics of mCRC patients receiving three or more lines of chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 682-682.	0.8	0
125	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS725-TPS725.	0.8	0
126	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. <i>Oncotarget</i> , 2019, 10, 4321-4332.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , The, 2018, 19, 812-824.	5.1	98
128	Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. <i>Annals of Oncology</i> , 2018, 29, 1195-1202.	0.6	13
129	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84
130	Biosimilars. <i>ESMO Open</i> , 2018, 3, e000321.	2.0	2
131	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , 2018, 38, 144-149.	0.9	10
132	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. <i>Annals of Oncology</i> , 2018, 29, 888-894.	0.6	104
133	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. <i>Journal of Genetic Counseling</i> , 2018, 27, 854-862.	0.9	5
134	Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. <i>Annals of Oncology</i> , 2018, 29, 669-680.	0.6	74
135	Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. <i>British Journal of Cancer</i> , 2018, 118, 1056-1061.	2.9	89
136	Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. <i>European Journal of Cancer</i> , 2018, 94, 199-205.	1.3	21
137	Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. <i>Clinical and Translational Oncology</i> , 2018, 20, 443-447.	1.2	27
138	Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 249-256.	1.1	23
139	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	5.1	333
140	EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. <i>Annals of Oncology</i> , 2018, 29, viii96.	0.6	3
141	EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. <i>Annals of Oncology</i> , 2018, 29, viii96-viii97.	0.6	2
142	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	0.8	704
143	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1079.	0.8	102
144	PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN. <i>Value in Health</i> , 2018, 21, S18.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. <i>Annals of Oncology</i> , 2018, 29, viii103.	0.6	3
146	Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial. <i>Annals of Oncology</i> , 2018, 29, viii91-viii92.	0.6	0
147	NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2 ⁻) breast cancer (BC). <i>European Journal of Cancer</i> , 2018, 92, S138.	1.3	0
148	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , 2018, 4, 41.	2.3	41
149	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii732.	0.6	8
150	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. <i>Cancer Management and Research</i> , 2018, Volume 10, 4517-4522.	0.9	4
151	Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 245-250.	0.7	3
152	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 4072-4080.	3.2	25
153	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
154	Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial. <i>European Journal of Cancer</i> , 2018, 92, S117-S118.	1.3	1
155	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
156	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 2897.	5.8	293
157	Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1939-1947.	0.6	107
158	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	13.9	1,472
159	The LILAC trial and the blooming of anticancer biosimilars. <i>Lancet Oncology</i> , The, 2018, 19, 861-863.	5.1	2
160	Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 627-634.	1.1	23
161	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC). <i>Cancer Research</i> , 2018, 78, PD3-06-PD3-06.	0.4	13
162	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2 ⁻) advanced breast cancer (ABC): Results from MONALEESA-3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1000-1000.	0.8	21

#	ARTICLE	IF	CITATIONS
163	The association of early toxicity and outcomes for patients treated with abemaciclib.. Journal of Clinical Oncology, 2018, 36, 1053-1053.	0.8	7
164	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ^{â€}) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b ComplEEment-1 trial.. Journal of Clinical Oncology, 2018, 36, 1056-1056.	0.8	4
165	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline <i>BRCA</i> mutation.. Journal of Clinical Oncology, 2018, 36, 1069-1069.	0.8	4
166	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. Journal of Clinical Oncology, 2018, 36, 3014-3014.	0.8	36
167	Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.. Journal of Clinical Oncology, 2018, 36, 501-501.	0.8	54
168	Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology, 2018, 36, 549-549.	0.8	3
169	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) Â± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS1115-TPS1115.	0.8	3
170	Prognostic and predictive factors in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 690-690.	0.8	1
171	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. Journal of Clinical Oncology, 2018, 36, 1521-1521.	0.8	8
172	Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases. Anticancer Research, 2018, 38, 3069-3077.	0.5	3
173	Abstract 3607: Quantitative dimensions of the PAM50 in breast tumors are prognostic and predict paclitaxel response. , 2018, , .		0
174	Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis. , 2018, , .		1
175	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3. , 2018, , .		3
176	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3. , 2018, 78, .		3
177	Simulation modeling approaches to answer clinically relevant questions in breast cancer low-risk populations. Annals of Translational Medicine, 2018, 6, S80-S80.	0.7	0
178	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	3.2	108
179	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2 ^{â€} Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Journal of Clinical Oncology, 2017, 35, 141-148.	0.8	327
180	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80

#	ARTICLE	IF	CITATIONS
181	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 ⁻) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	0.9	4
182	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
183	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 181-189.	1.1	11
184	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. <i>Clinical and Translational Oncology</i> , 2017, 19, 508-518.	1.2	13
185	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017, 144, 577-585.	0.6	34
186	Tuning up adjuvant endocrine therapy: the TEAM trial. <i>Lancet Oncology</i> , The, 2017, 18, 1145-1146.	5.1	1
187	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Future Oncology</i> , 2017, 13, 2137-2149.	1.1	7
188	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	1.9	13
189	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. <i>Breast Care</i> , 2017, 12, 296-302.	0.8	8
190	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
191	Neratinib for the treatment of HER2-positive early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 669-679.	1.1	22
192	RE: Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, 1.	3.0	2
193	A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2 ⁻ advanced breast cancer (BELLE-4). <i>Annals of Oncology</i> , 2017, 28, 313-320.	0.6	133
194	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. <i>Clinical and Translational Oncology</i> , 2017, 19, 341-356.	1.2	10
195	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 398-406.	0.7	29
196	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184181.	1.1	0
197	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. <i>GEICAM/2010-04 study. Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
198	Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC). <i>Cancer Research</i> , 2017, 77, P6-07-09-P6-07-09.	0.4	7

#	ARTICLE	IF	CITATIONS
199	Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.. Journal of Clinical Oncology, 2017, 35, 1003-1003.	0.8	8
200	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 2555-2555.	0.8	2
201	First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA).. Journal of Clinical Oncology, 2017, 35, 3082-3082.	0.8	3
202	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget, 2017, 8, 21930-21937.	0.8	17
203	Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.. Journal of Clinical Oncology, 2017, 35, 1012-1012.	0.8	0
204	A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2-advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy.. Journal of Clinical Oncology, 2017, 35, TPS1118-TPS1118.	0.8	0
205	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. Farmacia Hospitalaria, 2017, 41, 688-691.	0.6	3
206	Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3. Tumori, 2016, 102, S54-S56.	0.6	4
207	Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary hereditary cancer unit implementation. Annals of Oncology, 2016, 27, vi465.	0.6	0
208	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Annals of Oncology, 2016, 27, 1719-1725.	0.6	64
209	SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clinical and Translational Oncology, 2016, 18, 1243-1253.	1.2	34
210	SEOM guidelines 2016: an update. Clinical and Translational Oncology, 2016, 18, 1161-1162.	1.2	1
211	Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. Clinical Breast Cancer, 2016, 16, 364-371.	1.1	5
212	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Research and Treatment, 2016, 156, 507-515.	1.1	27
213	Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Annals of Oncology, 2016, 27, 1249-1256.	0.6	29
214	Final Survival Analysis of ROSE/TRIO-012. Journal of Clinical Oncology, 2016, 34, 3714-3715.	0.8	0
215	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. Journal of Clinical Oncology, 2016, 34, 3518-3528.	0.8	113
216	Endocrine therapy for hormone treatment-naïve advanced breast cancer. Breast, 2016, 28, 161-166.	0.9	7

#	ARTICLE	IF	CITATIONS
217	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	13.9	1,943
218	ACE and CXCL10 as predictive biomarkers in the LEA study. <i>Annals of Oncology</i> , 2016, 27, vi41.	0.6	0
219	Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs). <i>Annals of Oncology</i> , 2016, 27, vi507.	0.6	0
220	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , 2016, 56, 85-92.	1.3	4
221	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377.	5.1	444
222	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 447-455.	1.0	146
223	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 81-89.	1.1	38
224	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , 2016, 27, 379-390.	0.6	165
225	Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. <i>European Journal of Cancer</i> , 2016, 53, 75-83.	1.3	92
226	S-1 versus taxanes for HER2-negative metastatic breast cancer. <i>Lancet Oncology</i> , The, 2016, 17, 11-12.	5.1	3
227	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 96-106.	2.0	41
228	Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer. , 2016, , .		7
229	Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH). , 2016, , .		3
230	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	0.8	32
231	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2â€“ advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 507-507.	0.8	72
232	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS624-TPS624.	0.8	11
233	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10
234	A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e167.	0.5	6

#	ARTICLE	IF	CITATIONS
235	Outcomes of single versus double hormone receptor positive breast cancer.. Journal of Clinical Oncology, 2016, 34, 569-569.	0.8	1
236	Implication of MODEL of financing clinical research in breast cancer during the past two decades.. Journal of Clinical Oncology, 2016, 34, e14046-e14046.	0.8	0
237	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2016, 34, 593-593.	0.8	0
238	HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.. Journal of Clinical Oncology, 2016, 34, 515-515.	0.8	1
239	The implementation of a multidisciplinary hereditary cancer unit to increase the referral and preventive surgeries of breast cancer patients with genetic risk in a university hospital.. Journal of Clinical Oncology, 2016, 34, e13031-e13031.	0.8	0
240	nab-Paclitaxel dose and schedule in breast cancer. Breast Cancer Research, 2015, 17, 81.	2.2	21
241	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research, 2015, 17, 56.	2.2	30
242	El c�ncer de mama. Arbor, 2015, 191, a234.	0.1	6
243	Lower Breast Cancer Risk among Women Following Lifestyle Recommendations: A Case-Control Study in Spain.. International Journal of Epidemiology, 2015, 44, i136-i136.	0.9	0
244	SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups. Clinical and Translational Oncology, 2015, 17, 937-938.	1.2	2
245	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research, 2015, 21, 2065-2074.	3.2	59
246	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 141-148.	0.8	113
247	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. Journal of Clinical Oncology, 2015, 33, 1045-1052.	0.8	108
248	P105 The MAGIC survey in HR+, HER2+ breast cancer (BC): when might multigene assays be of value?. Breast, 2015, 24, S61.	0.9	0
249	Optimizing Adjuvant Taxanes in Early Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2334-2336.	0.8	1
250	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. European Journal of Cancer, 2015, 51, 685-696.	1.3	10
251	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Journal of Clinical Oncology, 2015, 33, 1574-1583.	0.8	146
252	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. Oncologist, 2015, 20, 474-482.	1.9	145

#	ARTICLE	IF	CITATIONS
253	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795.	0.8	56
254	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1129-1137.	0.9	37
255	Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 371-382.	1.1	73
256	Levels and predictors of persistent organic pollutants in an adult population from four Spanish regions. <i>Science of the Total Environment</i> , 2015, 538, 152-161.	3.9	26
257	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. <i>Oncologist</i> , 2015, 20, 111-112.	1.9	20
258	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. <i>Gut</i> , 2015, 64, 111-120.	6.1	93
259	Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. <i>Clinical and Translational Oncology</i> , 2015, 17, 180-196.	1.2	47
260	Abstract OT1-1-06: A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)., 2015, , .		1
261	Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study). <i>Cancer Research</i> , 2015, 75, OT1-1-12-OT1-1-12.	0.4	2
262	Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)., 2015, , .		2
263	Abstract P6-08-10: Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study. , 2015, , .		2
264	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 507-507.	0.8	55
265	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 508-508.	0.8	16
266	A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS1107-TPS1107.	0.8	9
267	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 117-117.	0.8	1
268	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0126096.	1.1	56
269	Abstract P5-15-08: Exercise intervention to run away from breast cancer treatment side effects: An integrative approach. , 2015, , .		0
270	Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo III breast cancer registry (1990-2001)., 2015, , .		0

#	ARTICLE	IF	CITATIONS
271	Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2 ⁺ breast cancer (BC) patients for whom multigene assays may be valuable. , 2015, , .		0
272	Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy.. Journal of Clinical Oncology, 2015, 33, 2524-2524.	0.8	0
273	Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.. Journal of Clinical Oncology, 2015, 33, 547-547.	0.8	1
274	Phase III Study of Palbociclib in Combination with Exemestane Vs. Capecitabine, in Hormonal Receptor (Hr) Positive/Her2 Negative Metastatic Breast Cancer (Mbc) Patients with Resistance to Non-Steroidal Aromatase Inhibitors (Nsa): Pearl Study (Geicam/2013-02_Cecog/Bc.1.3.006). Annals of Oncology, 2014, 25, iv134.	0.6	3
275	Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case ⁺ control EpiGEICAM study. British Journal of Cancer, 2014, 111, 1454-1462.	2.9	141
276	Adoption of Multi-Gene Assays in HR +, HER2 ⁺ Breast Cancer (BC) Patients in Europe: Results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) Survey. Annals of Oncology, 2014, 25, i5.	0.6	2
277	Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. Annals of Oncology, 2014, 25, i8.	0.6	1
278	Identification of genetic variants associated with capecitabine-induced hand ⁺ foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenetics and Genomics, 2014, 24, 231-237.	0.7	10
279	Vinflunine (Vfl) Plus Capecitabine (Cape) for Advanced Breast Cancer (Abc) Previously Treated with or Resistant to Anthracycline and Resistant to Taxane : a Phase 3 Study Versus Capecitabine. Annals of Oncology, 2014, 25, iv119.	0.6	1
280	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2014, 106, djt337-djt337.	3.0	218
281	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2 ⁺ breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research, 2014, 16, R38.	2.2	133
282	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. Journal of Genetic Counseling, 2014, 23, 108-113.	0.9	3
283	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient ⁺ s management and therapy selection. Clinical and Translational Oncology, 2014, 16, 386-394.	1.2	19
284	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncology, The, 2014, 15, 156-163.	5.1	171
285	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 ⁺ Positive Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3626-3633.	0.8	118
286	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	0.8	216
287	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer, 2014, 111, 1532-1541.	2.9	100
288	Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside. Current Breast Cancer Reports, 2014, 6, 79-87.	0.5	3

#	ARTICLE	IF	CITATIONS
289	Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.. Journal of Clinical Oncology, 2014, 32, 1013-1013.	0.8	1
290	Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxelâ€”Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.. Journal of Clinical Oncology, 2014, 32, 1051-1051.	0.8	3
291	A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting) Tj ETQq1 1 0.784314 rgBT /C HER2-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 587-587.	0.8	24
292	Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.. Journal of Clinical Oncology, 2014, 32, 9501-9501.	0.8	2
293	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori, 2014, 100, 144e-7e.	0.6	2
294	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. Journal of Clinical Oncology, 2014, 32, 11107-11107.	0.8	1
295	Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. Journal of Clinical Oncology, 2014, 32, 1602-1602.	0.8	0
296	Denosumab for the treatment of bone metastases in advanced breast cancer. Breast, 2013, 22, 585-592.	0.9	24
297	Costâ€”utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 381-391.	0.7	16
298	Healthâ€”Related Quality of Life With Adjuvant Docetaxelâ€”and Trastuzumabâ€”Based Regimens in Patients with Nodeâ€”Positive and Highâ€”Risk Nodeâ€”Negative, HER2â€”Positive Early Breast Cancer: Results from the BCIRG 006 Study. Oncologist, 2013, 18, 812-818.	1.9	20
299	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology, The, 2013, 14, 72-80.	5.1	192
300	Prognostic Significance of Progesterone Receptorâ€”Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology, 2013, 31, 203-209.	0.8	464
301	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. European Journal of Cancer, 2013, 49, 3763-3772.	1.3	133
302	Zooming in on the schedule of bone-modifying drugs. Lancet Oncology, The, 2013, 14, 575-576.	5.1	4
303	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 88-96.	5.1	128
304	Maintenance therapy in breast cancerâ€”many questions remain. Nature Reviews Clinical Oncology, 2013, 10, 370-372.	12.5	4
305	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	3.4	20
306	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment, 2013, 138, 149-155.	1.1	16

#	ARTICLE	IF	CITATIONS
307	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 457-466.	1.1	96
308	Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. <i>Onkologie</i> , 2013, 36, 363-367.	1.1	3
309	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2593-2599.	0.8	52
310	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2013, 18, 917-923.	1.9	41
311	Reply to Y. Yamamoto et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2517-2518.	0.8	2
312	A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. <i>International Journal of Oncology</i> , 2013, 42, 1778-1785.	1.4	11
313	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	2.2	80
314	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(−) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS652-TPS652.	0.8	7
315	Pharmacogenetic biomarkers for predisposition to toxicity to adjuvant FOLFOX/XELOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 390-390.	0.8	1
316	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS662-TPS662.	0.8	0
317	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2013, 31, 547-547.	0.8	1
318	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012, 23, 625-631.	0.6	106
319	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. <i>Clinical Cancer Research</i> , 2012, 18, 4841-4849.	3.2	124
320	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 469-475.	1.9	48
321	Differences in the Therapeutic Approach to Colorectal Cancer in Young and Elderly Patients. <i>Oncologist</i> , 2012, 17, 1277-1285.	1.9	59
322	Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer. <i>Circulation</i> , 2012, 126, 2749-2763.	1.6	198
323	Analysis of Fcγ3 Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3478-3486.	3.2	106
324	Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. <i>Supportive Care in Cancer</i> , 2012, 20, 2661-2668.	1.0	36

#	ARTICLE	IF	CITATIONS
325	Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 903-913.	1.1	41
326	Neoadjuvant treatments for triple-negative breast cancer (TNBC). <i>Annals of Oncology</i> , 2012, 23, vi35-vi39.	0.6	115
327	Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review. <i>European Journal of Cancer</i> , 2012, 48, 482-491.	1.3	12
328	AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. <i>European Journal of Cancer</i> , 2012, 48, S3.	1.3	1
329	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. <i>BMC Medical Genomics</i> , 2012, 5, 44.	0.7	250
330	Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study. <i>Oncology</i> , 2012, 82, 30-34.	0.9	7
331	Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes. <i>PLoS ONE</i> , 2012, 7, e42494.	1.1	7
332	Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial. <i>Annals of Oncology</i> , 2012, 23, ix115.	0.6	1
333	Neratinib (HKI-272) in the treatment of breast cancer. <i>Future Oncology</i> , 2012, 8, 671-681.	1.1	26
334	INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 12-21.	0.2	62
335	Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?. <i>Clinical and Translational Oncology</i> , 2012, 14, 163-168.	1.2	22
336	Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012, 21, 20-26.	0.9	30
337	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer. <i>Cancer</i> , 2012, 118, 241-247.	2.0	25
338	Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1001-1001.	0.8	1
339	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. <i>Journal of Clinical Oncology</i> , 2012, 30, 1008-1008.	0.8	14
340	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS652-TPS652.	0.8	1
341	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA671-LBA671.	0.8	36
342	Incidence and prediction of venous thromboembolism (VTE) in ambulatory patients (pts) with pancreas cancer receiving chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 368-368.	0.8	1

#	ARTICLE	IF	CITATIONS
343	Neutropenic fever and neoadjuvant intraperitoneal and systemic chemotherapy (DCF-like) in gastric cancer with peritoneal dissemination.. Journal of Clinical Oncology, 2012, 30, 144-144.	0.8	0
344	Family history record and hereditary cancer risk perception after the creation of a heredofamilial cancer unit in a Spanish hospital.. Journal of Clinical Oncology, 2012, 30, e12003-e12003.	0.8	0
345	Prognostic value of KRAS in terms of efficacy and safety of bevacizumab as neoadjuvant or conversion treatment in patients with colorectal liver metastasis.. Journal of Clinical Oncology, 2012, 30, e14058-e14058.	0.8	0
346	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. Journal of Clinical Oncology, 2012, 30, TPS670-TPS670.	0.8	0
347	Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With <i>HER2</i> -Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. Journal of Clinical Oncology, 2011, 29, 149-156.	0.8	222
348	Bevacizumab Treatment for Advanced Breast Cancer. Oncologist, 2011, 16, 1684-1697.	1.9	31
349	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 2011, 365, 1273-1283.	13.9	2,254
350	Assessment of Topoisomerase II \pm Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization. American Journal of Pathology, 2011, 178, 1453-1460.	1.9	59
351	3540 POSTER Perception of Hereditary Cancer Risk in a Medical Oncology Service: a Retrospective Study. European Journal of Cancer, 2011, 47, S258.	1.3	1
352	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology, The, 2011, 12, 369-376.	5.1	73
353	Understanding the value of antiangiogenic therapy in metastatic breast cancer. Current Opinion in Oncology, 2011, 23, S1.	1.1	4
354	Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. Journal of Clinical Bioinformatics, 2011, 1, 37.	1.2	20
355	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Breast, 2011, 20, S45.	0.9	0
356	Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment, 2011, 125, 273-278.	1.1	5
357	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Research and Treatment, 2011, 128, 127-136.	1.1	66
358	Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. Clinical and Translational Oncology, 2011, 13, 121-132.	1.2	8
359	Overview of preoperative radiochemotherapy in breast cancer: past or future?. Clinical and Translational Oncology, 2011, 13, 446-450.	1.2	6
360	A new era in the treatment of melanoma: from biology to clinical practice. Clinical and Translational Oncology, 2011, 13, 787-792.	1.2	9

#	ARTICLE	IF	CITATIONS
361	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004â€“05 study. <i>Annals of Oncology</i> , 2011, 22, 2591-2596.	0.6	28
362	Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1092-1100.	1.9	215
363	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	3.8	531
364	A Polymorphism in the <i>Cytidine Deaminase</i> Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Cancer Research</i> , 2011, 17, 2006-2013.	3.2	75
365	Alteration of Topoisomerase IIâ€“Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 859-867.	0.8	192
366	Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2â€“Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3877-3884.	0.8	135
367	P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer.. , 2011, , .		2
368	Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. <i>Anti-Cancer Drugs</i> , 2010, 21, S19-S22.	0.7	4
369	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 278-286.	1.2	2
370	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 149-157.	1.1	77
371	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 591-600.	1.1	38
372	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 121-131.	1.1	191
373	Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 169-176.	1.1	69
374	Missing data imputation using statistical and machine learning methods in a real breast cancer problem. <i>Artificial Intelligence in Medicine</i> , 2010, 50, 105-115.	3.8	381
375	Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2010, 103, 1524-1528.	2.9	18
376	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptorâ€“Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600.	0.8	553
377	BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 3988-3997.	3.2	37
378	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	13.9	169

#	ARTICLE	IF	CITATIONS
379	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361.	3.2	185
380	Reply to L.C. Panasci. <i>Journal of Clinical Oncology</i> , 2009, 27, e112-e113.	0.8	0
381	Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 1168-1176.	0.8	461
382	Reply to R.S. Mehta et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 3068-3069.	0.8	1
383	Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. <i>Oncologist</i> , 2009, 14, 1-11.	1.9	124
384	Reclassification of the members of the genus <i>Tetrathiobacter</i> Ghosh et al. 2005 to the genus <i>Advenella</i> Coenye et al. 2005. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2009, 59, 1914-1918.	0.8	44
385	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	1.2	15
386	Circulating tumour cells in locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 544-547.	1.2	11
387	Prognostic and predictive factors and genetic analysis of early breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 634-642.	1.2	7
388	A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1139-1148.	1.1	52
389	Docetaxel-related side effects and their management. <i>European Journal of Oncology Nursing</i> , 2009, 13, 49-59.	0.9	200
390	A Multicenter, Single-Arm Phase II Study of Pemetrexed Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 155-160.	1.1	2
391	TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 258-261.	1.1	28
392	Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 204.	2.2	27
393	Retrospective subset analyses in early breast cancer revisited. <i>Lancet Oncology</i> , The, 2009, 10, 1136-1137.	5.1	0
394	Unravelling the mystery of the TACT trial. <i>Lancet</i> , The, 2009, 373, 1662-1663.	6.3	5
395	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. <i>Clinical and Translational Oncology</i> , 2008, 10, 552-559.	1.2	1
396	Time-to-progression in breast cancer: A stratification model for clinical trials. <i>Breast</i> , 2008, 17, 239-244.	0.9	2

#	ARTICLE	IF	CITATIONS
397	Trans-generational radiation-induced chromosomal instability in the female enhances the action of chemical mutagens. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 640, 16-26.	0.4	5
398	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , 2008, 44, 353-365.	1.3	17
399	REMOVED: Docetaxel-related side effects and their management. <i>European Journal of Oncology Nursing</i> , 2008, 12, 253-268.	0.9	34
400	Corrigendum to "Docetaxel-related side effects and their management" [European Journal of Oncology Nursing 12 (2008) 253-268]. <i>European Journal of Oncology Nursing</i> , 2008, 12, 479.	0.9	1
401	PMS66 WILLINGNESS TO PAY VS. QUALITY ADJUSTED WAGES AS ALTERNATIVE WAYS TO MEASURE THE BURDEN OF DISEASE IN SPAIN: AN APPLICATION TO BALLOON KYPHOPLASTY. <i>Value in Health</i> , 2008, 11, A557-A558.	0.1	0
402	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814.	3.0	208
403	Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 2636-2643.	0.8	54
404	Elementary, My Dear Watson. <i>Journal of Clinical Oncology</i> , 2007, 25, 1815-1816.	0.8	8
405	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3399-3406.	0.8	273
406	A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3652-3659.	3.2	28
407	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology</i> , The, 2007, 8, 219-225.	5.1	181
408	Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR. <i>Analytical Biochemistry</i> , 2007, 364, 153-158.	1.1	1
409	Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. <i>Breast</i> , 2007, 16, 127-131.	0.9	18
410	Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). <i>Breast Cancer Research and Treatment</i> , 2007, 101, 215-223.	1.1	57
411	BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2007, 25, LBA1008-LBA1008.	0.8	25
412	Molecular biology of breast cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 7-14.	1.2	33
413	Circulating tumoral cells lack circadian-rhythm in hospitalized metastatic breast cancer patients. <i>Clinical and Translational Oncology</i> , 2006, 8, 826-829.	1.2	7
414	Introduction. <i>Seminars in Oncology</i> , 2006, 33, 1.	0.8	0

#	ARTICLE	IF	CITATIONS
415	Clinical Experience With Pemetrexed in Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 15-18.	0.8	10
416	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006, 17, 1205-1212.	0.6	171
417	Docetaxel, Doxorubicin and Cyclophosphamide (the TAC regimen): An Effective Adjuvant Treatment for Operable Breast Cancer. <i>Women's Health</i> , 2006, 2, 527-537.	0.7	13
418	Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report. <i>Journal of Clinical Oncology</i> , 2006, 24, 10505-10505.	0.8	14
419	Trastuzumab Associated with Successive Cytotoxic Therapies Beyond Disease Progression in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 325-329.	1.1	46
420	Capecitabine plus docetaxel combination therapy. <i>Cancer</i> , 2005, 103, 2455-2465.	2.0	22
421	Life-threatening Complications From Doxorubicin-Docetaxel Chemotherapy for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2166.	3.8	1
422	The Global Breast Cancer Burden: Variations in Epidemiology and Survival. <i>Clinical Breast Cancer</i> , 2005, 6, 391-401.	1.1	445
423	Adjuvant Docetaxel for Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 2302-2313.	13.9	892
424	Epirubicin+cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , 2004, 15, 79-87.	0.6	69
425	Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2587-2593.	0.8	115
426	Phase II Study of Pegylated Liposomal Doxorubicin plus Vinorelbine in Breast Cancer with Previous Anthracycline Exposure. <i>Clinical Breast Cancer</i> , 2004, 5, 353-357.	1.1	24
427	Cancer therapy with unloaded monocyte-derived dendritic cells in patients with inoperable pancreatic and gall bladder cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2569-2569.	0.8	1
428	Vinorelbine as a 96-Hour Continuous Infusion in Heavily Pretreated Patients with Metastatic Breast Cancer: A Cooperative Study by the GEICAM Group. <i>Clinical Breast Cancer</i> , 2003, 3, 399-404.	1.1	14
429	Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 968-975.	0.8	358
430	Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. <i>Annals of Oncology</i> , 2003, 14, 1246-1252.	0.6	43
431	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 7, 14). <i>Journal of Clinical Oncology</i> , 2003, 21, 833-842.	0.6	145
432	Moving forward with capecitabine: a glimpse of the future. <i>Oncologist</i> , 2002, 7 Suppl 6, 29-35.	1.9	4

#	ARTICLE	IF	CITATIONS
433	Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. <i>Breast Cancer Research</i> , 2001, 3, 183-91.	2.2	43
434	Methotrexate, Uracil and Tegafur, and Leucovorin Chemotherapy for Patients With Breast Cancer in Progression After High-Dose Chemotherapy With Peripheral Blood Progenitor Cell Transplant. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 617-621.	0.6	4
435	Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. <i>Annals of Oncology</i> , 2000, 11, 85-90.	0.6	23
436	Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against <i>Streptococcus pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997, 16, 512-516.	1.3	15
437	Effect of oxodipine and nifedipine on guinea-pig ileum. <i>General Pharmacology</i> , 1988, 19, 771-4.	0.7	0